Drug Profile
Cannabidiol - Vivera Pharmaceuticals
Latest Information Update: 28 May 2023
Price :
$50
*
At a glance
- Originator Vivera Pharmaceuticals
- Class Analgesics; Anti-inflammatories; Anti-ischaemics; Antiacnes; Antibacterials; Antiepileptic drugs; Antihyperglycaemics; Antihyperlipidaemics; Antineoplastics; Antiparkinsonians; Antipsoriatics; Antipsychotics; Antirheumatics; Anxiolytics; Behavioural disorder therapies; Cannabinoids; Cardiovascular therapies; Cyclohexenes; Drug withdrawal therapies; Heart failure therapies; Hepatoprotectants; Muscle relaxants; Neuroprotectants; Obesity therapies; Opioid analgesics; Resorcinols; Skin disorder therapies; Small molecules
- Mechanism of Action 5-HT1 serotonin receptor modulators; Cannabinoid receptor CB1 inverse agonists; Cannabinoid receptor CB2 inverse agonists; Transient receptor potential channel modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Alcoholism; Opioid-related disorders; Pain
Most Recent Events
- 28 May 2023 No recent reports of development identified for research development in Alcoholism in USA (Sublingual)
- 28 May 2023 No recent reports of development identified for research development in Opioid-related-disorders in USA (Sublingual)
- 28 May 2023 No recent reports of development identified for research development in Pain in USA (Sublingual)